Lundbeck broadens phase III trial of Vyepti in children

Previous participants in Lundbeck trials are being brought together in a new phase III study that aims to investigate the long-term safety of use of migraine drug Vyepti in childhood.

Photo: Thomas Borberg

Children and young people who have previously participated in clinical trials of migraine drug Vyepti have now been offered the chance to remain in treatment for a longer period.

Lundbeck is starting a trial where 610 people aged between 6 and 17 will receive quarterly infusions of Vyepti, in either a 100 or 300 mg dose. The aim is to investigate the long-term safety profile of using Vyepti over a longer period, Lundbeck writes in the study description on ClinicalTrials.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs